Verro Barbara, Lo Casto Antonio, Saraniti Carmelo
Division of Otolaryngology, Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, 90127 Palermo, Italy.
Division of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, 90127 Palermo, Italy.
Int J Surg Case Rep. 2023 Sep;110:108736. doi: 10.1016/j.ijscr.2023.108736. Epub 2023 Aug 29.
Laryngeal carcinoma represents the 22nd most common cancer worldwide. Thyroid metastasis from laryngeal cancer is extremely rare. Overall, thyroid gland involvement by metastatic carcinoma represents about 1.1-2.1 % among thyroid malignant diseases.
A male in his 70s came to our Otolaryngology Unit with a laryngeal squamous cell carcinoma (cT3). Total laryngectomy and bilateral neck dissection were performed. Histological examination revealed a pT3 carcinoma with sub-massive metastasis of the Delphian node. The patient underwent close follow-up. After eight months, neck examination revealed a suspected nodule in the right thyroid lobe. A right thyroid lobectomy was performed, and histological assessment revealed a nodule with squamous carcinoma metastasis in the superior pole of the thyroid lobe. The remaining thyroid tissue was affected by multinodular macrofollicular goitre. The patient underwent adjuvant therapy. One year after the second surgery, he showed no signs of recurrence.
Thyroid gland metastasis from laryngeal carcinoma is a very rare occurrence. In literature, we found only three articles that describes thyroid metastasis in overall 7 patients affected by laryngeal squamous cell carcinoma. Positive Delphian lymph node is usually related to poor prognosis: in 2007 a study reported tumour recurrence in 15 out of 25 patients with metastatic Delphian lymph node within the first two years of surgery.
Thyroid gland metastasis from laryngeal carcinoma is rare; so close follow-up of oncologic patients is mandatory and, most of all, the positive Delphian node should not be underestimated for its predictive value.
喉癌是全球第22大常见癌症。喉癌转移至甲状腺极为罕见。总体而言,转移性癌累及甲状腺在甲状腺恶性疾病中约占1.1 - 2.1%。
一名70多岁男性因喉鳞状细胞癌(cT3)前来我院耳鼻喉科。行全喉切除术及双侧颈部淋巴结清扫术。组织学检查显示为pT3癌,伴德尔菲淋巴结大量转移。患者接受密切随访。八个月后,颈部检查发现右侧甲状腺叶有可疑结节。行右侧甲状腺叶切除术,组织学评估显示甲状腺叶上极有鳞状细胞癌转移结节。其余甲状腺组织患有多结节性大滤泡性甲状腺肿。患者接受了辅助治疗。第二次手术后一年,他未出现复发迹象。
喉癌转移至甲状腺非常罕见。在文献中,我们仅发现三篇文章描述了总共7例喉鳞状细胞癌患者发生甲状腺转移的情况。德尔菲淋巴结阳性通常与预后不良相关:2007年一项研究报告称,25例德尔菲淋巴结转移患者中有15例在手术后的头两年内出现肿瘤复发。
喉癌转移至甲状腺罕见;因此,肿瘤患者必须进行密切随访,最重要的是,德尔菲淋巴结阳性因其预测价值不应被低估。